

	Type	L #	Hits	Search Text	DBs	Time Stamp	C o m m e n t s	E r r o r s
1	BRS	L1	8735	zinc adj (sulphate\$1 or sulfate\$1)	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:21		0
2	BRS	L6	2948	ZnSO?sub.4	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:22		0
3	BRS	L1 1	81	Zn adj SO?sub.4	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:22		0
4	BRS	L1 6	1519	ZnSO4	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:22		0
5	BRS	L2 1	12280	1 or 6 or 11 or 16	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:22		0
6	BRS	L2 6	87	21 same (protien\$1 or protein\$1) same ((salt\$3 adj out) or precipitat\$5)	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:25		0

	Type	L #	Hits	Search Text	DBs	Time Stamp	C o m m e n t s	E r r o r s
7	BRS	L3 1	1	26 and rifampicin	USPAT; EPO; JPO; DERWEN T	2001/12/17 14:09		0
8	BRS	L3 6	60	26 and (HPLC or chromatograph\$9)	USPAT; EPO; JPO; DERWEN T	2001/12/17 14:08		0
9	BRS	L4 1	34	36 and (propanol or acetonitrile or benzene or toluene or dichloromethane or chloroform)	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:30		0
10	BRS	L4 6	4	41 and ("340" adj nm)	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:44		0
11	BRS	L5 6	2	5135875.pn.	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:36		0
12	BRS	L6 1	0	51 and 56	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:36		0

	Type	L #	Hits	Search Text	DBs	Time Stamp	C o m m e n t s	E r r o r s
13	BRS	L6 6	1	26 and 56	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:36		0
14	BRS	L7 1	7	26 and ("340" adj nm)	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:45		0
15	BRS	L5 1	30	41 not 46	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:56		0
16	BRS	L7 6	21	51 and (blood or urine or tear\$1 or (bod\$2y adj fluid\$1))	USPAT; EPO; JPO; DERWEN T	2001/12/17 13:58		0
17	BRS	L8 1	0	56 and (HPLC or chromatograph\$9)	USPAT; EPO; JPO; DERWEN T	2001/12/17 14:09		0
18	BRS	L8 6	11	hydrophobic\$5 with rifampicin	USPAT; EPO; JPO; DERWEN T	2001/12/17 14:11		0

	Type	L #	Hits	Search Text	DBs	Time Stamp	C o m m e n t s	E r r o r s
19	BRS	L9 1	2502	rifampin or rifaldazine or rifamycin or rifampicin	USPAT; EPO; JPO; DERWEN T	2001/12/17 14:12		0
20	BRS	L9 6	1	26 and 91	USPAT; EPO; JPO; DERWEN T	2001/12/17 14:12		0

FILE 'REGISTRY' ENTERED AT 14:21:36 ON 17 DEC 2001

L1 0 S ZINC SULPHATE
L2 249 S ZINC SULFATE

FILE 'CAPLUS' ENTERED AT 14:22:03 ON 17 DEC 2001

L3 9760 S L2
L4 11540 S L3 OR (ZINC SULFATE) OR (ZINC SULPHATE)
L5 62 S L4 AND (PROTEIN OR PROTIEN) AND ((SALT? OUT) OR PRECIPITAT?)
L6 9 S L5 AND (TOLUENE OR ACETONITRILE OR CHLOROFORM OR BENZENE OR D

FILE 'STNGUIDE' ENTERED AT 14:24:26 ON 17 DEC 2001

FILE 'CAPLUS' ENTERED AT 14:25:37 ON 17 DEC 2001

L7 9126 S (RIFAMPICIN OR RIFAMPIN OR RIFALDAZINE OR RIFAMYCIN)
L8 1 S L5 AND L7
L9 1 S L6 AND L7
L10 0 S L7 AND HPLC.TI. AND ZHANG.AU.
L11 0 S L7 AND ZHANG.AU.
L12 0 S 109002Y
L13 0 S 109002Y.AN.
L14 0 S 109002Y/AN
L15 0 S L7 AND ZHANG/AU
L16 19 S L7/TI AND HPLC/TI

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2001 ACS
AN 1990:30169 CAPLUS
DN 112:30169
TI An improved micro-scale **protein precipitation**
procedure for HPLC assay of therapeutic drugs in serum
AU Lam, Stanley; Malikin, Galina
CS Albert Einstein Coll. Med., Bronx, NY, 10461, USA
SO J. Liq. Chromatogr. (1989), 12(10), 1851-72
CODEN: JLCHD8; ISSN: 0148-3919
DT Journal
LA English
AB A **protein pptn.** procedure for prepg. serum-free
supernatant for HPLC of therapeutic drugs is described. **Protein**
pptn. is facilitated by adding small amts. of **zinc**
sulfate to the serum followed by a polar org. solvent (methanol,
acetonitrile) with subsequent centrifugation. Since the procedure
involves few pipetting steps, sample loss is minimized and recovery and
precision are improved. Correlation coeffs. of 1-5% are accomplished for
the assays without internal stds. The **protein pptn.**
procedure is applicable to the HPLC of drugs in serum at min. detection
levels of 0.5 mg/mL and 0.1 mg/mL by UV and fluorescence detection, resp.
The method has been applied to the detn. of several drugs in human blood
serum.

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2001 ACS
AN 1992:15243 CAPLUS
DN 116:15243
TI Reversed-phase liquid chromatographic method for the simultaneous
determination of the antimalarial drugs sulfadoxine, pyrimethamine,
mefloquine and its major carboxylic metabolite in plasma
AU Bergqvist, Yngve; Eckerbom, Solveig; Larsson, Helena; Malekzadeh, Monireh
CS Dep. Clin. Chem., Falun Cent. Hosp., Falun, S-791 82, Swed.
SO J. Chromatogr. (1991), 571(1-2), 169-77
CODEN: JOCRAM; ISSN: 0021-9673
DT Journal
LA English
AB A high-performance liq. chromatog. method for the simultaneous detn. of
sulfadoxine, pyrimethamine, mefloquine and the carboxylic metabolite of
mefloquine in plasma is described. After the **proteins** have been
pptd. with a combination of **zinc sulfate** and
acetonitrile contg. two internal stds., pyrimethamine and
mefloquine are extd. as bases and sulfadoxine and the carboxylic
metabolite of mefloquine as ion-pairs with tetrabutylammonium. The drugs
are sepd. by HPLC on a 3 .mu.m octadecylsilica column with UV detection at
229 nm. The method is simple and reliable and enables the simultaneous
detn. of the drugs in 600-.mu.L plasma samples with a sensitivity suitable
for std. drug monitoring purposes.

L16 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2001 ACS
AN 1997:56454 CAPLUS
DN 126:109002
TI Study on HPLC assay for the plasma concentration of
rifampicin and its pharmacokinetics of microsphere formulation
AU Zhang, Wanguo; Jiang, Xuetao; Zhu, Caijuan
CS College of Pharmacy, The Second Military Medical University, Shanghai,
200433, Peop. Rep. China
SO Zhongguo Kangshengsu Zazhi (1996), 21(4), 273-276
CODEN: ZKZAEY; ISSN: 1001-8689
PB Zhongguo Kangshengsu Zazhishe
DT Journal
LA Chinese
AB Rifampicin (RFP) concn. in rabbit plasma was detd. by a HPLC assay. The
recovery rate was 102.04%, the linear range was 0.4-12.0 $\mu\text{g mL}^{-1}$ and
the RSD was <2%. The pharmacokinetics study of RFP in rabbits showed that
microsphere formulation could sustain the drug release, thus injection of
REP microspheres in rabbits gave a more stable and long-lasting plasma
concn.